Daratumumab-based Treatment of Monoclonal Gammopathy-associated Angioedema Due to Acquired C1-inhibitor Deficiency
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
Daratumumab-based treatment could control severe, treatment-refractory, life-threatening angioedema due to acquired C1-inhibitor deficiency associated with monoclonal gammopathy.
References
1.
Zand L, Rajkumar S, Leung N, Sethi S, El Ters M, Fervenza F
. Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits. J Am Soc Nephrol. 2021; 32(5):1163-1173.
PMC: 8259683.
DOI: 10.1681/ASN.2020101541.
View
2.
Dimopoulos M, Oriol A, Nahi H, San-Miguel J, Bahlis N, Usmani S
. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023; 41(8):1590-1599.
PMC: 10022849.
DOI: 10.1200/JCO.22.00940.
View
3.
Fermand J, Bridoux F, Dispenzieri A, Jaccard A, Kyle R, Leung N
. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018; 132(14):1478-1485.
DOI: 10.1182/blood-2018-04-839480.
View
4.
Levi M, Cohn D, Zeerleder S, Dziadzio M, Longhurst H
. Long-term effects upon rituximab treatment of acquired angioedema due to C1-inhibitor deficiency. Allergy. 2018; 74(4):834-840.
DOI: 10.1111/all.13686.
View
5.
Baeza M, Gonzalez-Quevedo T, Caballero T, Guilarte M, Lleonart R, Varela S
. Angioedema Due to Acquired Deficiency of C1-Inhibitor: A Cohort Study in Spain and a Comparison With Other Series. J Allergy Clin Immunol Pract. 2021; 10(4):1020-1028.
DOI: 10.1016/j.jaip.2021.11.018.
View